Gland Pharma Reports 58% Profit Increase in Q2 on Strong CDMO Growth
Gland Pharma reported a 58% year-on-year rise in consolidated net profit to around Rs 291 crore for Q2 FY27, driven by strong growth in its CDMO business and expanding customer base. Revenue increased 23% to Rs 1,833 crore, while EBITDA rose 53% to Rs 480 crore. The company launched four molecules in the US and increased R&D spending focused on complex product development. Executive Chairman Srinivas Sadu highlighted ongoing investments in manufacturing and innovation to capitalize on global outsourcing opportunities.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (69/100). Lens Score 35/100.
Outlets measured: news18, thefinancialexpress. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thefinancialexpress broke this story on 6 Nov, 12:58 pm. Other outlets followed.
- 1